Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) plus binimetinib (BIM) plus cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
Scott Kopetz, Axel Grothey, Rona Yaeger, Pieter-Jan AR Cuyle, Sanne Huijberts, Jan HM Schellens, Elena Elez, Marwan Fakih, Clara Montagut Viladot, Marc Peeters, Jayesh Desai, Takayuki Yoshino, Fortunato Ciardiello, Harpreet Singh Wasan, Kati Maharry, Janna Christy-Bittel, Ashwin Gollerkeri, Eric Van Cutsem, Josep Tabernero
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019
688 Background: BRAFV600E mutation occurs in 10%-15% of patients (pts) with mCRC and confers a poor prognosis. After first-line therapy, standard second-line therapies provide limited benefit, with objective response rates (ORRs) < 10%, and overall survival (OS) of 46 months (mo). BEACON CRC (NCT02928224) is a 3-arm phase 3 trial of triplet therapy with the BRAF inhibitor ENCO + MEK inhibitor BINI + antiEGFR antibody CETUX vs ENCO + CETUX vs a control arm (irinotecan/FOLFIRI + CETUX) in pts with BRAFV600E mCRC in the second or third-line setting. A safety lead-in (SLI) of the triplet therapy was conducted in 30 pts prior to initiation of the randomized part of the trial. Previously repor..View full abstract